Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Shire PLC on In-Line Q4

The 8 Most Undervalued Stocks Fund Managers Are Buying
28 Stocks Moving In Monday's Pre-Market Session

In a report published Friday, Deutsche Bank reiterated its Buy rating on Shire PLC (NASDAQ: SHPG), but lowered its price target from $110.00 to $108.00.

Deutsche Bank noted, “Shire reported largely in line Q4 non-GAAP EPS of $1.58. Total revs of $1.20B were also in-line. Vyvanse sales reached $257M (+18% Y/Y) but would have been $30M higher without a destock. As for other strong performers, Intuniv posted a 24% Y/Y increase to reach $81M (+$4M vs our est) and Elaprase sales reached $139M (+12% Y/Y), $7M better than our est. AXR revs of $82M came in $3M below consensus due to higher gross to net sales deductions. All other key product franchises were largely in-line. On the negative side, after 2 slow launch yrs in Europe, Resolor will no longer be promoted. Second, Dermagraft came in even weaker than expected, missing our $36M est by $17M.”

Shire PLC closed on Thursday at $93.68.

Latest Ratings for SHPG

Oct 2017FBR CapitalInitiates Coverage OnBuy
Aug 2017Evercore ISI GroupInitiates Coverage OnOutperform
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for SHPG
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (SHPG)

View Comments and Join the Discussion!

Partner Center